Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26022339 | 0.80 | ALDH1A1 (0.59) | SMN1; SMN2TP53MAPTPOLB | |
| SCHEMBL13531815 | 0.79 | MEN1 (0.66) | SMN1; SMN2TP53MAPTMEN1KMT2A | |
| SCHEMBL26022343 | 0.78 | ALDH1A1 (0.50) | HRH3SMN1; SMN2TP53MAPTMEN1 | |
| SCHEMBL3180468 | 0.78 | MEN1 (0.51) | SMN1; SMN2TP53MAPTMEN1KMT2A | |
| SCHEMBL3176428 | 0.75 | GPR119 (0.49) | HRH3SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL10022381 | 0.75 | TP53 (0.65) | SMN1; SMN2TP53MAPTMEN1KMT2A | |
| SCHEMBL6109389 | 0.75 | HRH3 (0.69) | HRH3 | |
| SCHEMBL25903917 | 0.74 | HRH3 (0.60) | HRH3 | |
| SCHEMBL3192299 | 0.74 | HPGD (0.49) | SMN1; SMN2TP53MAPTMEN1KMT2A | |
| SCHEMBL10066942 | 0.73 | TP53 (0.57) | SMN1; SMN2TP53MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | HRH3 2402/4885SMN1; SMN2 235/4885TP53 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.